EGFR Tests - In Vitro Diagnostic Market Analysis and Forecast Model

Globally, lung cancer is the second most common cancer in men and the third most common cancer in women. There are two main types of lung cancer; small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC accounting for approximately 80-90% of all lung cancer cases. The 5-year survival rate for patients with stage IV disease is less than 5% as majority of patients present with the advanced or metastatic disease at diagnosis. EGFR is a member of the receptor tyrosine kinase family and a major factor in regulating cellular proliferation, invasion, metastasis, angiogenesis, and inhibition of apoptosis. EGFR is one of the most routinely tested biomarkers in NSCLC. EGFR mutation assays have evolved over the past decade. With numerous detection methods currently in clinical use, the consensus is that an ideal assay should be sensitive, effectively covering all clinically relevant targets with use of limited samples, and cost efficient. Most EGFR mutations found in adenocarcinoma are located in the tyrosine kinase domain. The most frequently encountered mutations are in-frame deletions in exon 19 (around 45%) and a point mutation in exon 21 (L858R), which together account for over 85% of described mutations. These mutations strongly correlate with NSCLC patients responding to EGFR therapies such as the tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib, afatinib, and icotinib.


Who should buy this report?

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

  • CMO executives who must have deep understanding of the EGFR Tests marketplace to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Key Highlights

Competitive Assessment

Currently marketed EGFR Tests and evolving competitive landscape:

  • Insightful review of the key industry trends.
  • Annualized total EGFR Tests market revenue by segment and market outlooks from 2015–2028.
  • Granular data on total procedures, units, average selling prices and market values by segment.

Reasons to buy

The model will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving EGFR Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the EGFR Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific EGFR Tests market from 2015-2028.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

  • F. Hoffmann-La Roche Ltd (Roche Diagnostics International Ltd)
  • Qiagen NV
  • Agilent Technologies Inc
  • Illumina Inc
  • Thermo Fisher Scientific Inc
  • Abbott Laboratories
  • NimaGen BV
  • Agena Bioscience ...
  • F. Hoffmann-La Roche Ltd (Roche Diagnostics International Ltd)
  • Qiagen NV
  • Agilent Technologies Inc
  • Illumina Inc
  • Thermo Fisher Scientific Inc
  • Abbott Laboratories
  • NimaGen BV
  • Agena Bioscience Inc
  • BML Inc
  • Takara Bio Inc
  • New England Biolabs Inc
  • Amoy Diagnostics Co Ltd
  • Panagene Inc
  • Others


Discounts available for multiple report purchases.
+44 (0) 161 359 5813

Join our mailing list

Saved reports